Novartis had an impressive start to the year with strong financial performance and significant product approvals, leading to an upgraded full-year guidance. However, there are ongoing challenges, particularly with the rollout of Pluvicto and the potential impacts of tariffs and geopolitical uncertainties.

Company Guidance -

Q3 2025

In the recent Novartis Q1 2025 earnings call, the company reported robust financial performance with a 15% increase in sales and a 27% rise in core operating income. The core margin improved by 400 basis points to reach 42.1%, contributing to an upgrade in the full-year 2025 guidance. Notable achievements include Kisqali's 56% growth in constant currency and Entresto's 22% sales increase. The company also highlighted successful approvals for Pluvicto, Vanrafia, and Fabhalta, and significant developments in their pipeline, such as the global submission for remibrutinib and positive readouts for OAV-101 IT gene therapy. Novartis remains confident in its midterm growth outlook, targeting 5% plus sales growth and planning strategic investments in U.S. manufacturing and R&D.

Strong Financial Performance

Novartis delivered a double-digit sales growth of 15% and a core operating income up 27% for Q1 2025. The core margin reached 42.1%, reflecting a 400 basis points improvement.

Significant Product Approvals

Approvals for Pluvicto, Vanrafia, and Fabhalta in their relevant indications were achieved. Additionally, a global submission for remibrutinib in CSU and OAV-101 IT gene therapy for SMA was made.

Strong Performance of Key Brands

Kisqali grew by 56%, Kesimpta by 43%, Pluvicto by 21%, and Leqvio by 72% in constant currency, showcasing robust growth across priority brands.

Upgraded Full-Year Guidance

Novartis upgraded its full-year 2025 guidance to high single-digit sales growth and low double-digit core operating income growth.

Novartis AG (CH:NOVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:NOVN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 28, 2025	2025 (Q3)	1.77 / -	2.06	―	―	―
Jul 17, 2025	2025 (Q2)	1.89 / 1.94	1.581	22.84% (+0.36)	―	―
Apr 29, 2025	2025 (Q1)	1.70 / 1.83	1.445	26.67% (+0.39)	―	―
Jan 31, 2025	2024 (Q4)	1.45 / 1.59	1.228	29.41% (+0.36)	―	―
Oct 29, 2024	2024 (Q3)	1.56 / 1.65	1.397	18.39% (+0.26)	―	―
Jul 18, 2024	2024 (Q2)	1.49 / 1.58	1.392	13.61% (+0.19)	―	―
Apr 23, 2024	2024 (Q1)	1.35 / 1.44	1.301	11.04% (+0.14)	―	―
Jan 31, 2024	2023 (Q4)	1.33 / 1.23	1.157	6.18% (+0.07)	―	―
Oct 24, 2023	2023 (Q3)	1.34 / 1.40	1.202	16.15% (+0.19)	―	―
Jul 18, 2023	2023 (Q2)	1.32 / 1.39	1.187	17.24% (+0.20)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:NOVN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	CHF95.12	CHF93.34	-1.87%
Apr 29, 2025	CHF93.40	CHF94.21	+0.87%
Jan 31, 2025	CHF90.56	CHF92.28	+1.90%
Oct 29, 2024	CHF96.36	CHF92.43	-4.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Novartis AG (CH:NOVN) report earnings?

Novartis AG (CH:NOVN) is schdueled to report earning on Oct 28, 2025, TBA (Confirmed).

What is Novartis AG (CH:NOVN) earnings time?

Novartis AG (CH:NOVN) earnings time is at Oct 28, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Novartis AG stock?

The P/E ratio of Novartis AG is N/A.

What is CH:NOVN EPS forecast?

CH:NOVN EPS forecast for the fiscal quarter 2025 (Q3) is 1.77.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing